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Background: Small for gestational age (SGA) babies are at high risk of 
perinatal mortality. We aimed to determine the potential to reduce 
perinatal mortality by improving antenatal detection of SGA babies in 
Scotland. 
Methods: We conducted a retrospective population study of all 
singleton SGA babies born in the 15 Consultant-led maternity units in 
Scotland in a 3-month period (1st Dec 2014 to 28th Feb 2015 inclusive).  
Demographic and pregnancy outcome data were extracted from 
Scottish birth records for all pregnancies; case note review was 
performed for all SGA cases [defined as birthweight less than the 10th 
centile for their gestational age at delivery as defined by the 
appropriate sex-specific UK-WHO Child Growth Standards]. 
Results: The SGA rate in Scotland was 5.5% (673/12218; 95% 
confidence interval [CI] 5.1, 5.9) and 27.6% (186/673; 95% CI 24.3, 31.2) 
of SGA cases were identified prior to delivery. SGA was associated with 
18.2% (12/66; 95% CI [10.1%, 30.0%) of all perinatal deaths. The 
majority (10/12, 83.3%) of SGA babies who died had been identified as 
SGA in the antenatal period. There was no difference in perinatal 
mortality whether SGA was detected or not (5.4% [10/186; 95% CI 2.8, 
10.0] in the SGA detected group vs 0.4% [2/487 [95% CI 0.3, 2.2] in the 
non-detected group after adjusting for risk factors for SGA, gestation 
at delivery and birthweight centile (Adjusted odds ratio [AOR] 0.85 
[95% CI 0.5, 1.5], p=0.556). 
Conclusions: Despite only around a quarter of SGA babies being 
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identified antenatally, the potential to reduce perinatal mortality in 
the Scottish population by improving SGA detection is limited. Only a 
minority of perinatal deaths occurred in SGA babies; and in the 
majority of these SGA was detected antenatally.
Keywords 
Pregnancy, Small for Gestational Age, Stillbirth, Perinatal Morbidity, 
Birthweight
 
Page 2 of 15
Wellcome Open Research 2020, 5:35 Last updated: 04 MAR 2021
Abbreviations
AC Abdominal Circumference
BMI Body Mass Index
EFW Estimated Fetal Weight
GROW Gestation Related Optimal Weight
NHS ISD NHS National Services Scotland, Information Services 
Division
INTERGROWTH-21st International Fetal and Newborn Growth 
Consortium for the 21st Century
RCOG Royal College of Obstetricians and Gynaecologists
SFH Symphysis Fundal Height
SGA Small for Gestational Age
SMR02 Scottish Morbidity Record 02
WHO World Health Organization 
Introduction
Small for gestational age (SGA) babies are at increased risk of 
perinatal mortality1. Obstetric practice aims to identify these 
babies and deliver them at a time that minimises harm. It is 
assumed that improving detection of SGA will reduce the 
number of stillbirths, with some estimating a 20% reduction in 
mortality with optimal detection of SGA2. However, signifi-
cant resources are required for SGA detection protocols, and 
instituting them may cause harm – through false positive 
diagnoses (causing unnecessary early delivery)3.
Ultrasound examination is commonly used for the detection of 
SGA, with fetal measurements recorded on fetal growth charts. 
In the UK and USA selective ultrasound screening is most 
often used, with referral for ultrasound based on maternal risk 
factors or symphysis-fundal height measurement. More recently, 
it was suggested that universal ultrasound is a more effective 
screening for the SGA fetus. Whilst a randomised controlled 
trial (RCT) showed that universal ultrasound tripled SGA detec-
tion in nulliparous women when compared with current selective 
screening, the potential to reduce perinatal mortality is less 
certain.
We conducted a retrospective population cohort study of all 
babies born SGA in Scotland in a 3-month period. The objective 
was to determine the potential to reduce perinatal mortality by 
improving antenatal detection of SGA babies. Specifically, we 
aimed to determine the current rate of antenatal SGA detection 
in Scotland; and to compare perinatal outcomes between SGA 
babies detected antenatally and those not detected (to identify 
the number of deaths that could, potentially, be prevented 
through SGA detection and early delivery).
Methods
Study design and setting
A retrospective population-based cohort study of babies born 
in the 15 consultant-led maternity units with >1000 deliveries 
in 2014 (including their alongside midwifery units) in Scotland 
between 1st December 2014 and 28th February 2015 inclusive 
(includes >98% Scottish Births4).
Database
The cohort was identified from the Scottish Morbidity 
Record 02 (SMR02; the Maternity Inpatient and Day Case data-
set) that is collated by the NHS National Services Scotland, Infor-
mation Services Division (NHS ISD). SMR02 collects episode 
level data on all hospital deliveries in Scotland. The dataset 
includes patient identifiable information, maternal and baby 
characteristics and is estimated to be 99% complete across all 
health boards during the study period5. The missing data is due to 
a combination of home births (which are not recorded on SMR02 
as there is no hospital admission) and missing data from maternity 
unit submissions.The National Records of Scotland is a civil 
registration system of all births in Scotland and was used to cross 
reference delivery numbers by the NHS ISD. There is a legal 
requirement to register all live births and all stillbirths (after 
24 weeks gestation) within 21 days of birth.
Ethics and anonymisation
As this was a quality improvement project formal ethical 
review was not required. Each individual maternity unit had a 
designated project lead who completed a "Confidential Data 
Release Request" that was approved by the Consultant Lead in 
each unit and the NHS National Services Caldicott Guardian. Data 
were de-identified in the delivering maternity unit and only ano-
nymised data were returned centrally to the project coordinator.
Population
The study population was women with singleton pregnancies 
delivering at 24 weeks gestation or more, in the 15 Consultant- 
Led NHS Maternity Units with >1000 deliveries in 2014 (includ-
ing their alongside midwifery units) in Scotland between 
1st December 2014 and 28th February 2015 inclusive.
The SGA cohort included all babies (live births and stillbirths) 
with a birth weight less than the 10th centile for their gesta-
tional age as defined by the appropriate sex-specific UK-WHO 
Child Growth Standards6, used for all Scottish children to 
define growth disturbance in childhood (as recorded in the Per-
sonal Child Health Record that every child receives). The WHO 
charts define optimal growth standards based on worldwide 
data of healthy children up to 4 years. These charts have been 
combined with birth data for gestations 23–42 weeks from the UK 
1990 growth reference charts to produce the UK-WHO charts6. 
The 10th centile was chosen as this threshold is used as a 
definition in guidelines from WHO and countries including the 
UK, USA and Canada7.
A comparator "non-SGA group" was all singleton deliveries 
(live births and stillbirths) that were not identified as SGA (i.e. 
the SGA cohort) by the NHS ISD review of the SMR02 data set 
(see below). These deliveries were presumed to be at or above 
the 10th centile as defined by the UK-WHO Child Growth 
Standards6.
Data extraction: outcomes, exposures and variables
SGA cohort. The SGA cohort was identified by NHS ISD and 
case details were forwarded to the project lead at each hos-
pital, who performed detailed case note review. The SGA 
cohort included all live births identified as being less than the 
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10th centile for gestational age in SMR02. As the formula used 
by NHS ISD to calculate the birth weight centiles from the 
UK-WHO charts was only applied to live births, all stillbirths less 
than the 10th centile for 42 weeks gestational age (i.e. <3283g 
for boys and <3165g for girls) were identified to ensure that no 
cases were missed, with inclusion being clarified at the time of 
case note review.
A detailed case review of maternity and neonatal records of the 
cases was performed by each project lead using a standard-
ised proforma (Extended data8). Birth weight centile was veri-
fied and additional variables (see below) were extracted from 
the hand-held maternity notes, hospital paper notes and/or the 
maternity paperless patient records systems that was in use in 
each unit. Data on APGAR scores were extracted from SMR02.
Non-SGA cohort. The non-SGA comparator group data was identi-
fied by the NHS ISD from the study population by excluding the 
cases that had been identified as SGA. A detailed hospital case 
note review was not performed for the non-SGA group. Instead 
NHS ISD extracted data from SMR02 on pre-specified variables 
to enable comparison between the SGA and non-SGA cohorts 
(see below).
Outcomes and variables
Outcomes. The primary outcome was perinatal mortality in babies 
in whom SGA was not detected compared to those in whom 
SGA was detected. We used the definitions of perinatal mortal-
ity from the UK Perinatal Mortality Surveillance Report9 (see 
Table 1). We have reported early neonatal death as this reflects 
obstetric events more closely than deaths up to 28 days.
Planned secondary outcomes were any admission to a neonatal 
unit of any level and APGAR score <7 at five minutes. These are 
both markers of perinatal morbidity.
SGA cohort. SGA detection was defined as documentation of 
SGA, fetal growth restriction or intrauterine growth restriction 
or small for dates in the case record prior to the onset of labour. 
Where it was not clear, or data were missing, it was presumed 
that SGA was not detected. The method of detection was 
defined as ultrasound diagnosed (ultrasound scan findings of an 
abdominal circumference or estimated fetal weight as <10th 
centile when measured on reference growth chart used by the 
local hospital at that time) or as clinically- suspected (deter-
mined by a reduced symphysis-fundal height measurement or 
clinical palpation, according to local hospital protocol, without 
ultrasound confirmation).
Additional variables collected at case note review in the SGA 
cohort were maternal characteristics including age, body mass 
index (BMI) at booking and ethnicity. Baby characteristics 
included gestation at delivery (in days) and birth weight (in 
grams). Mode of delivery was classified as elective caesarean sec-
tion (scheduled prior to the onset of labour), emergency caesarean 
section (unscheduled or performed during labour), operative 
vaginal delivery (forceps or ventouse) or spontaneous vaginal 
delivery.
Data regarding five clinical risk factors for SGA were also 
extracted including previously having a SGA baby (parous 
women), maternal age over 40 years at delivery, smoking over 
10 cigarettes at the time of booking (data on any smoking in 
pregnancy was also collected for comparison with non-SGA 
cohort), hypertensive disorders in pregnancy (diagnosis of pre- 
existing hypertension, pregnancy induced hypertension and pre-
eclampsia as per the individual unit's diagnostic criteria) and 
any attendance with reduced fetal movements. These are major 
risk factors in the Royal College of Obstetricians and Gynae-
cologists (RCOG)’s Green Top Guideline on SGA detection7 
that should trigger growth ultrasound screening and had high 
levels of completeness in antenatal records.
Non-SGA comparator group. Data extracted from SMR02 for 
the non-SGA comparator group included maternal characteristics 
(age, ethnicity, BMI at booking and smoking of any cigarettes 
during pregnancy) and baby details (gestation at delivery, birth 
outcome [live birth, stillbirth or neonatal death], admission to a 
neonatal unit, APGAR’s <7 at 5 minutes).
Growth ultrasound and biometry data. For each pregnancy in 
the SGA cohort, the number of growth ultrasound scans per-
formed was recorded. Growth ultrasounds were defined as those 
scans performed where the main intention was to obtain fetal 
biometry, from 22 weeks gestation onwards.
Study size
Initial scoping of the SMR02 data suggested that the incidence 
of SGA babies less than 10th centile was approximately 5%, 
and we estimated an SGA detection rate of 25% based on local 
audit data (in line with published literature)10–12. We therefore 
estimated we would require a sample of 621 SGA babies to 
establish the SGA detection rate with 95% confidence level and 
absolute precision of 3%. Based on an annual delivery rate of 
approximately 56000 in Scotland13, we calculated a 3-month 
data collection would provide a study population of around 
13000 and a study cohort of 650 SGA babies (allowing for 2% 
home births which are not recorded on SMR02 and missing 
data of ~5%).
Data analysis
Data were de-identified at source, and anonymised data was 
collated and cleaned on a central database. Statistical analysis 
was performed using SPSS, version 22.0 and R studio, Version 
1.1.453. Where data was normally distributed mean and standard 
Table 1. Perinatal mortality definitions.
Outcome Definition
Live Birth Any baby born with signs of life9
Stillbirth Any baby delivered at or after 24+0 
weeks gestation, showing no signs of life, 
irrespective of when the death occurred9
Early Neonatal Death Death of any live born infant (born 
after 20+0 weeks gestation) before 7 
completed days after birth9
Perinatal Mortality Stillbirth or Early Neonatal Death9
Page 4 of 15
Wellcome Open Research 2020, 5:35 Last updated: 04 MAR 2021
deviation were calculated. The t test was used to calculate 
p values. Where data was not normally distributed median and 
interquartile ranges were calculated. For data where proportions 
were calculated, Pearson’s chi squared test (with Yates’ correc-
tion) or Fisher’s Exact Test (for numbers 10 or less) were used. 
Significance was defined as p<0.05. 95% confidence intervals have 
also been reported. Logistic regression was performed to explore 
the influence of antenatal SGA detection on perinatal mortality 
and neonatal unit admission. Presence of one or more maternal 
risk factor for SGA (dichotomous variable), gestational age at 
delivery (continuous variable) and birthweight centile (continu-
ous variable) were included in the model. Results are presented 
as unadjusted and adjusted odds ratio (OR and AOR; 95% 
confidence intervals, (CI)). Cases with missing fields were 
excluded from regression analysis.
To explore the effect of missing data on the cohort, we com-
pared the SGA cohort with and without exclusion of sites with 
one or more missing data points in >15% cases (4 sites 
excluded; see supplementary Table S1 in extended data8).
Where there was missing data on antenatal SGA detection, SGA 
was presumed not to have been detected, and these cases were 
included in the denominator in analyses. The impact of includ-
ing missing data on SGA detection in the denominator was 
explored using a sensitivity analysis excluding cases with 
missing data on SGA detection (25 cases excluded; see 
supplementary Table S2 in extended data8).
Results
During the 3-month study period (1st December 2014 – 28th 
February 2015) there were 12619 births in Scotland, of which 
12218 were singleton deliveries. There were 12175 singleton 
live births (with 25 [0.2%] neonatal deaths) and 43 stillbirths 
(0.35%). A flowchart is provided in Figure 1.
In total, 791 babies (756 live births and 35 stillbirths) were 
identified from the SMR02 as being potentially SGA. The 
remaining 11427 babies formed the non-SGA comparator 
group.
Following case note review 92 of 756 (12.2%) live births 
were re-classified as not SGA either due to discrepant birth-
weight or discrepant gestation. Due to anonymisation of data at 
source these babies could not be re-identified to include in the 
comparator group and were excluded from all subsequent analyses. 
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Of the 35 stillbirths with potential SGA (birth weights <10th cen-
tile for 42 weeks gestational age) 9 were found on case review 
to be <10th centile for gestation at delivery, and were included 
in the SGA cohort. The 25 stillbirths who were not SGA were 
included in the non-SGA comparator group for comparison of 
perinatal mortality rates (giving a total of 11453 babies for this 
comparison).
This gave a total cohort of 673 SGA babies, with an incidence 
of 5.5% (673/12218; 95% confidence interval [CI] 5.1, 5.9). 
Complete data was available for 623 cases (89.9%), with one or 
more field missing from 68 maternity records. The number of 
fields with missing data for each variable are included in 
Table 2 and Table 3. Four units had >15% of cases with at least 
one missing data field. A comparison was made between the full 
SGA cohort and the cohort with these units excluded. The 
two cohorts were similar (see supporting information S1 Table), 
thus all units were included in the analysis presented.
Of the 673 SGA babies, 183 were less than the 3rd centile 
(27.2% [95%CI 23.3, 31.3] of SGA babies; 1.5% [95% CI 1.1, 
1.9] of singleton births); 144 between the 3rd and 5th centiles 
(21.4% [95% CI 17.5, 25.5] of SGA babies; 1.2% [95% CI 0.8, 
1.6] of singleton births) and 346 were above the 5th centile 
(51.4% [95% CI 47.5, 55.6] of SGA babies; 2.9% [95% CI 2.5, 
3.2] of Scottish Births).
Participating units
All 15 consultant-led maternity units in Scotland with >1000 
births/year contributed data.
Comparison of SGA and non-SGA pregnancies
The details of the SGA and non-SGA cohorts are shown in 
Table 2.
As expected, the SGA cohort was higher risk than the rest of 
the Scottish population, with more primiparous women (59.1% 
[398/673; 95% CI 55.3, 62.9] versus 43.0% [4918/11427; 
95% CI 42.1, 44.0], p<0.0001) and smokers (37.1% [250/673; 
95% CI 33.6, 40.9] versus 16.4% [1870/11427; 95% CI 
15.7,17.1, p<0.0001) in the SGA group compared to the 
non-SGA group.
The SGA cohort was statistically significantly slightly younger 
than the non-SGA group (29.1 years versus 29.6 years; p=0.015) 
but this is unlikely to be of clinical significance. There was 
no difference in the proportion of women older than 40 years at 
delivery (2.7% [18/673; 95% CI 1.6, 4.2] versus 2.4% [270/ 
11427; 95% CI 2.1, 2.7], p=0.7), the mean gestation at deliv-
ery (39+1 weeks [95% CI 39+1, 39+2] versus 39+2 weeks 
[95% CI 39+1, 39+3], p=0.38) or the Caesarean Section rate 
(32.4% [217/673; 95% CI 28.4, 36.3] versus 31.1% [3548/ 
11427; 95% CI 30.2, 31.9], p=0.54) between the two groups.
Ethnicity recorded was recorded as unknown more fre-
quently in the non-SGA group (data from SMR02 routine data; 
20.2% [2312/11427] unknown ethnicity) than in the SGA 
group (data obtained from hand searching of case notes; 2.8% 
[19/673] ethnicity unknown; p<0.0001). We therefore did not 
perform formal comparison of ethnicity as any differences are 
likely to reflect ascertainment bias.
Perinatal mortality was higher in the SGA group than in the 
non-SGA group (1.78% [12/673; 95% CI 0.9, 3.1] versus 0.44% 
[52/11451; 95% CI 0.4, 0.6], p=0.0002) as was the stillbirth 
rate (1.34% [9/673; 95% CI 0.6 -2.3] versus 0.30 [34/11451; 95% 
CI 0.2, 0.4], p=0.0003). The numbers of early neonatal death 
were small and no statistically significant differences were seen 
between the two cohorts (0.45% live births [3/664; 95% CI 0.1- 
1.3] versus 0.18% live births [20/11419; 95% CI 0.1, 0.3], p=0.13). 
A higher proportion of SGA livebirths were admitted to the 
neonatal unit (14.3% [96/664; 95% CI 11.7, 17.1] versus 8.2% 
[939/11419; 95% CI 7.7, 8.8], p<0.0001).
Antenatal detection of SGA and comparison of outcomes 
in SGA detected versus SGA not detected groups
In 25 of the 673 SGA cases (3.9%) data was missing on 
whether SGA was detected antenatally. These cases were pre-
sumed not to have been detected antenatally in the subsequent 
analysis. 27.6% (186/673; 95% CI 24.3, 31.2) of SGA cases were 
identified prior to delivery (see Table 3). Of the 186 detected 
cases, 162 (87.1%) were diagnosed by ultrasound scanning, 23 
(12.4%) were identified on clinical assessment (i.e. symphysis- 
fundal height measurements, not confirmed with ultrasound). In 
one case (0.54%) the method of detection was not documented. 
454/673 women (67.5%; 95% CI 63.8%, 71.0%) who had an 
SGA baby had at least one growth ultrasound performed, with 
322/673 (47.9%; 95% CI 44.0%, 51.7%) having more two or 
more growth scans performed in the pregnancy.
There was a higher proportion of mothers with one or more 
risk factors for SGA in the group with antenatal detection of 
SGA, than in the group where SGA was undetected (73.7% in 
SGA detection group [137/186; 95% CI 66.6,79.7] vs 56.7% in 
SGA not detected group [276/487; 95%CI 52.1, 61.1], p<0.0001) 
(Table 3). Babies in whom SGA was detected were born earlier 
(mean gestation at delivery 37+4 weeks [95% CI 37+2, 37+6] 
in SGA detected group vs 39+6 weeks [95% CI 39+5, 39+6] in 
the SGA not detected group [p<0.0001]) and were lighter (mean 
birthweight centile 4.2 [95% CI 4.0, 4.4]vs 5.4 [95%CI 5.3, 
5.5], p<0.0001) than babies where growth restriction was not 
detected (Table 3).
The perinatal mortality was higher in the detection group 
compared to non-detected group (5.4% [10/186; 95% CI 2.8, 
10.0] in the SGA detected group vs 0.4% [2/487 [95% CI 0.3, 2.2] 
in the non-detected group [p=0.0007]) (Table 3). However, the 
increased odds of perinatal mortality did not remain statistically 
significant after adjusting for presence of maternal risk factors 
for SGA, gestation at delivery and birthweight centile 
(Unadjusted odds ratio [OR] of perinatal mortality in SGA 
detected group vs non-detected group 13.8 [95% CI 3.6, 90.2], 
p<0.0001; Adjusted odds ratio [AOR] 2.4 [95% CI 0.4, 18.1], 
p=0.345). Similarly, the unadjusted rate of neonatal unit 
admission was higher in the detection group (25.1% [45/179 
livebirths; 95% CI 19.1, 32.3] vs 10.6% [51/483 livebirths; 
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Table 2. Demographics of study population. Small for gestational age (SGA) cohort vs non-SGA cohort. Statistical Tests 
*Pearson’s Chi Square with Yates’ Correction †Unpaired 2-sided t test ‡Fisher’s Exact Test §denominator 664 livebirths 





95% CI Missing (%) Non-SGA 
comparator 
(n=11427)
95% CI Missing (%) p
Maternal Demographic
Primiparous (%) 398 (59.1) 55.3 62.9 4918 (43.0) 42.1, 44.0 26 (0.2) p<0.0001*
Maternal age at delivery 
(mean [sd] years)
29.1 (6.0) 28.8, 29.3 1 (0.2) 29.6 (5.7) 29.5, 29.7 0 p= 0.015†
BMI (mean [sd] kg/m2) 25.4 (5.5) 25.2, 25.7 3 (0.4) 26.2 (6.0) 26.1, 26.3 136 (1.2) p=0.0004†
Maternal age >40years at 
delivery (%)
18 (2.7) 1.6, 4.2 1 (0.2) 270 (2.4) 2.1, 2.7 0 p=0.7*
Any smoking (%) 250 (37.1) 33.6, 40.9 4 (0.6) 1870 (16.4) 15.7, 17.1 394 (3.5) p<0.0001*
Ethnicity 19 (2.8) 2312 (20.2) p<0.0001*
White British (%) 532 (78.2) 74.9, 81.2 7627 (66.8) 65.9, 67.6 -
White Non-British (%) 51 (7.5) 5.7, 9.8 377 (3.2) 2.9, 3.6 -
Asian (%) 52 (7.7) 5.8, 10.0 355 (3.1) 2.8, 3.5 -
African (%) 15 (2.2) 1.3, 3.7 127 (1.1) 0.9, 1.3 -
Other (%) 11 (1.6) 0.9, 3.0 629 (5.5) 5.1, 5.9 -
Delivery Details
Gestation at delivery 
(mean weeks+days [sd 
days])
39+1(17) 39+1, 39+2 0 39+2 (28) 39+1, 
39+3
39 (0.3%) p=0.38†
Mode of Delivery 0 2 (0.02%)
Vaginal birth (%) 365 (54.2) 50.4, 58.3 6459 (56.5) 55.6, 57.4 p= 0.26*
Operative Vaginal Delivery 
(%)
91 (13.5) 9.7, 17.5 1418 (12.4) 11.8, 13.0 p=0.43*
Caesarean Section (%) 217 (32.2) 28.4, 36.3 3548 (31.1) 30.2, 31.9 p=0.54*
Pregnancy Outcome
Perinatal mortality (%) 12 (1.78) 0.9, 3.1 54 (0.47) 0.4, 0.6 p<0.0002‡
Stillbirth (%) 9 (1.34) 0.6, 2.3 34** (0.30) 0.2, 0.4 p<0.0005‡
Neonatal death (%) 3§ (0.45) 0.1, 1.3 20¶ (0.18) 0.1, 0.3 p=0.13‡
Neonatal unit admission 
(%)
96§ (14.3) 11.7, 17.1 19 (2.8) 939¶ (8.2) 7.7, 8.7 69 (0.6) p<0.0001*
95% CI 8.0, 13.7; p<0.0001) but this relationship was not seen 
after adjusting for maternal risk factors, gestation and centile 
at delivery (OR of neonatal unit admission in SGA detected 
group vs non-detected group 2.6 [95% CI 1.7, 4.1], 
p<0.0001; Adjusted odds ratio [AOR] 0.85 [95% CI 0.5, 1.5], 
p=0.556).
Descriptions of the 12 perinatal death cases are given in 
supplementary material Table S3. Ten of the 12 perinatal deaths 
(83.3%) were identified as SGA antenatally. Six of these 
were extremely preterm (less than 28 weeks gestation) and/or 
extremely growth restricted (birthweight 500 grams or less). 
Three (one neonatal death and two stillbirths) occurred at or 
more 36 weeks, despite being identified as being SGA.
Only two deaths were not detected as being SGA antenatally. 
One had growth scans performed, but SGA was not identified 
– and delivered at 41 weeks gestation. The other stillbirth with 
undetected SGA was a preterm stillbirth at 29 weeks gestation, 
with no preceding growth scans performed.
A sensitivity analysis was performed comparing the SGA 
detected cohort with the cohort where SGA was not detected 
antenatally, excluding the 25 cases with missing data on 
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95% CI Missing (%) SGA not 
detected 
(n=487)
95% CI Missing (%) P
Maternal Demographic
Primiparous 102 (54.8) 47.4, 62.1 296 (60.8) 56.3, 65.1 p= 0.189*
Maternal age at delivery (mean 
[sd] years)
29.1 (6.2) 28.7, 29.6 1 (0.5) 29.0 (5.9) 28.7, 29.3 0 p= 0.793†
BMI (mean [sd] kg/m2) 25.0 (5.5) 24.6, 25.4 25.6 (5.5) 25.3, 25.8 p= 0.184†
Ethnicity 5 (2.7) 14 (2.9) p=1†
White (%) 165 (88.7) 83.1, 92.7 411 (84.4) 80.8, 87.4 p= 0.193*
Not white (%) 16 (8.6) 5.16, 13.83 62 (12.7) 10.0, 16.1 p= 0.173*
Risk Factors
One or more risk factors (%) 137 (73.7) 66.6, 79.7 276 (56.7) 52.1, 61.1 11 (2.3) p<0.0001*
Smoker >10 cigarettes per 
day (%)
65 (35.0) 28.2, 
42.3
4 (2.2) 136 (27.9) 24.0 32.2 2 (0.4) p=0.102*
Maternal age >40years at 
delivery (%)
5 (2.7) 1.0, 6.5 1 (0.5) 13 (2.7) 1.5, 4.6 0 p=1.0*
Previous SGA baby (%) 46 (24.7) 18.8, 31.7 64 (13.1) 10.3, 16.5 16 (3.3) p=0.0004*
Hypertensive disorder (%) 21 (11.3) 7.3, 17.0 1 (0.5) 29 (6.0) 4.1, 8.5 22 (4.5) p=0.028*
Reduced fetal movements (%) 65 (35.0) 28.2, 42.3 3 (1.6) 116 (23.8) 20.2 27.9 23 (4.7) p= 0.005*
Pregnancy Outcome
Gestation at delivery (mean 
weeks+days [sd days])





4.2 (2.8) 4.0, 4.4 5.4, (2.8) 5.3, 5.5 p<0.0001†
Perinatal mortality (%) 10 (5.4) 2.8, 
10.0
2 (0.4) 0.26, 
2.21
0.0001c
Stillbirth (%) 7 (3.8) 1.7, 7.9 2 (0.4) 0.07, 1.6 p=0.003‡
Neonatal death (%) 3§ (1.7) 0.4, 5.2 0** 0.0, 1.0 p=0.03*
Neonatal unit admission (%) 45§ (25.1) 19.1 32.3 51** (10.6) 8.0, 13.7 19 (3.9) p<0.0001*
*Pearson’s Chi Square with Yates’ Correction
†Unpaired 2-sided t test
‡Fisher’s Exact Test
§denominator 179 live births
**denominator 483 live births
antenatal SGA detection. Findings were similar to when these 
25 cases were included in the SGA not detected group 
Discussion
We found that 5.5% of babies in Scotland were SGA at birth 
and perinatal mortality was higher in these babies compared 
to non-SGA babies, confirming that these babies are a high-
risk obstetric population. The overall antenatal SGA detection 
rate in Scotland was 27.3%. This detection rate, although 
low, is consistent with other published studies10,12,13,15,
Overall, we found that the potential to decrease perinatal 
mortality by improving detection of SGA in our population was 
much more limited than the 20% previously estimated2. Firstly, 
only one fifth of perinatal deaths occurred in SGA babies; 
thus, optimising SGA detection could not prevent the majority of 
perinatal deaths. Secondly, more than two thirds of SGA perinatal 
deaths were detected as being SGA antenatally, with only two of 
the SGA babies who died not recognised as being SGA antena-
tally. One of these was an antenatal stillbirth at 29 weeks gesta-
tion, when the risks of iatrogenic preterm delivery of SGA babies 
are significant and neonatal outcomes less certain. Only one 
stillbirth was at term (greater than 37 weeks gestation), when 
death could more certainly be considered preventable by early 
delivery. Growth ultrasound had been performed in this case, 
but SGA was not detected. Extrapolating from our data, we 
Page 8 of 15
Wellcome Open Research 2020, 5:35 Last updated: 04 MAR 2021
calculate that even if all of SGA babies in singleton pregnancies 
were identified antenatally and identification could prevent 50% 
of perinatal mortality (which are both very optimistic estimates) 
then we could expect a maximal reduction in perinatal mortality 
of 0.5 per 1000 births, equating to around a 10% reduction in 
current perinatal mortality rates (5.1 per 1000[2]). In reality, 
SGA detection rates are only 60% even with universal screening 
for growth restriction[20], and there are very limited options for 
managing severely SGA babies. Thus, the potential for reduc-
ing mortality through improving detection of SGA is even more 
limited.
Our findings contrast to previously published UK data2, in our 
study perinatal outcomes were worse in babies where SGA was 
detected antenatally, compared to SGA babies who had not 
been recognised antenatally, with cases where SGA was rec-
ognised having higher rates of stillbirth, neonatal death and 
neonatal unit admission. Our findings likely reflect the fact that 
more severe SGA was more likely to be detected, with higher 
rates of maternal risk factors, and lower delivery gestations 
birthweight centiles in the detected group. When these factors 
were adjusted for, we found no persistent association between 
antenatal SGA detection and perinatal mortality or neonatal unit 
admission. These data need to be interpreted cautiously as the 
numbers are small, and the analysis is post hoc. Our results are 
consistent with the analysis of a French study where SGA preg-
nancies identified antenatally had worse neonatal outcomes than 
those SGA pregnancies not detected16. In addition, in the French 
study, those pregnancies which were wrongly identified as 
SGA (i.e. false positives) had worse outcomes than the true nega-
tive population (i.e. not SGA and correctly identified as that), 
highlighting the potential for iatrogenic harm in wrongly 
diagnosing SGA3,16.
Strengths and limitations
Strengths of this study are that it is population based, with sup-
plementary case note review to ensure data quality in the SGA 
cohort. We used the WHO 1990 birthweight centile charts for 
the diagnosis of SGA, which is clinically relevant as these are 
used for the diagnosis of growth disorders in Scottish children. We 
found 5.6% births less than the 10th centile, which is in line 
with other recent UK studies17 and reflects the right shifting 
of birthweight centiles in high income countries over time.
Our study has several limitations. Firstly, SGA is a surrogate 
used to identify babies that are growth restricted. Some babies 
that do not reach their growth potential will have birthweights 
above the10th centile (i.e. won’t be SGA by our definition), and 
these would not be detected within our study. Secondly, stillborn 
babies lose weight in utero between death and delivery due to the 
process of maceration18, therefore the number of stillbirths associ-
ated with SGA are likely to be overestimated if (as in our study) 
unadjusted birthweights are used. This means the true perinatal 
mortality rate in SGA babies is likely to be lower than our find-
ings suggest, and our estimates of the potential to reduce perinatal 
mortality through detection of SGA are overoptimistic. Thirdly, 
our focus was on detection of SGA and we did not collect data 
on the management of pregnancies, which is likely to be an 
important factor in the perinatal outcomes of SGA babies. 
Fourthly, the comparator non-SGA group data was extracted 
from NHS ISD and not subject to case review thus comparisons 
between SGA and non-SGA babies may be at risk of ascertain-
ment bias. Finally, we did not assess false positive rates i.e. those 
babies delivered due to a suspicion of SGA that subsequently 
were found to be of normal birthweight.
Conclusions
Although avoiding any preventable perinatal death is extremely 
important, our findings suggest that focussing resources on 
improving detection of SGA alone is unlikely to have a major 
impact on perinatal mortality rates. To improve perinatal outcomes, 
we should focus on optimising high-quality care based on our 
current knowledge alongside commissioning high quality 




The metadata for this study was provided by NHS ISD who are 
the data controllers. The Caldicott Guardian agreement by 
which we sourced the data does not allow for data sharing of the 
metadata as it is identifiable at a patient and a practitioner level. 
Any suitably qualified researcher with the appropriate approval 
would be able to obtain this data directly from NHS ISD. 
Researchers would need to complete a “Confidential Data 
Release Form” available from NHS National Services Scotland 
to gain approval. They can then use our study proforma to request 
the required data from NHS ISD (see extended data).
Extended data
Open Science Framework: An evaluation of the potential to 
improve perinatal outcomes by improving antenatal detection of 
small for gestational age babies in Scotland: a retrospective 
population cohort study. https://doi.org/10.17605/OSF.IO/EWTMB8
This project contains the following extended data:
-   Study Proforma.xls (Proforma used for data extraction)
-    Supporting info.pdf (PDF containing Supplementary 
Tables 1–3)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Abstract 
Method - Please mention the data analysis strategy in the research. 
 
Result - Provide the total singleton birth engaged. Instead of using 5.5% followed with number, 
use XX% (95%, XX-XX). There is confusion in presenting the data that “there was no difference in 
perinatal mortality whether SGA was detected or not…” as it presents 5.4% (95% CI, 2.8-10.0) vs 
0.4% (95% CI, 0.3-2.2). This data shows difference in two group without adjustment. I think after 
adjusting to risk factors the risk might have changed, so either present the adjusted risk or rather 
not present it. It is confusing. 
 
Conclusion - The authors present “Despite only around a quarter of SGA being identified 
antenatally, ….” This data has not been presented in the result of abstract, either present it or 
remove it from the abstract conclusion. 
  
Main text 
Introduction - A couple of sentences on the national and global burden of SGA and death 
attributed to it will provide the importance of the study. 
  
Method - My main concern is the timing of detection of SGA during antenatal period. The timing 
of detection of SGA during antenatal period corresponds with the preventive measures used for 
managing the pregnancy and birth. The author needs to describe it well. Can the authors also 
distinguish between antenatal and intrapartum stillbirth? This is a key value, as the timing of 




The flow diagram is confusing. A STROBE flow diagram for cohort design needs to be redone. 
 
Table 3 also needs to provide the categorization of antepartum and intrapartum stillbirth. Also, 
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the timing of detection of SGA antenatally with the number of perinatal death is important, either 
a graph on this or a separate supplementary table will be interesting. 
  
Discussion 
One other key factor is infection during pregnancy not been captured by the registry, this needs to 
be mentioned in the limitation section.
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health policy on antenatal screening methods. 
  
The research sets out to determine whether there is scope for improving the rate of antenatal 
detection of the small for gestational age (SGA) fetus and, if so, whether this is likely to impact 
significantly on perinatal mortality. This was a population-based cohort study in Scotland. The 
article concludes that during the 3-month study period, antenatal detection of Scottish SGA was 
similar to that in published reports from other national settings, but that only a small proportion 
of perinatal mortality occurred in babies who were also SGA. In the vast majority of these, SGA had 
been antenatally detected anyway, so it was concluded that there was little room for improving 
national perinatal death rates through improved antenatal detection of SGA. 
  
The article is well-written with only a small number of typographical errors. It could therefore 
benefit from an additional proofread. The text is easy to understand. 
  
My key comments are targeted to areas in which I think the article could be improved:
The number of perinatal deaths in SGA babies (n=12) is too small to make a conclusion 
about the potential to improve rates of perinatal death by increasing SGA detection. It is 
unclear in the text why the population cohort was limited to 3 months of births. I realise 
that the burden of reviewing maternity records for 791 babies is high, and less biased than 
only reviewing the rate of SGA detection in records for babies with perinatal deaths. 
However, given the primary aim of the study was to assess the potential of improving SGA 
detection for babies who die in the perinatal period, data collection on SGA detection in a 
larger cohort of SGA deaths would be more informative. I suggest you: (a) provide reasons 
for the limited time frame (b) indicate why you chose the strategy of assessing SGA 
detection in all babies rather than targeted in perinatal deaths and (c) suggest future work 
to cover the latter. 
 
1. 
On this same point, the aim of the study and the primary outcome is ‘perinatal mortality in 
babies in whom SGA was not detected compared to those in whom SGA was detected’, 
however the statistical power of the study was calculated on the rate of SGA detection in the 
whole population. Where the power calculation is not targeted to the primary outcome, this 
needs to be explained. I expect this was the decision because it was not expected to be 
possible for the study to be powered adequately for the primary outcome. The text should 




As someone who is familiar with birth weight percentile charts, I was still a bit confused 
about the interchangeable use of the terms UK1990, UK-WHO, WHO-1999 and WHO birth 
weight charts. In particular, the second paragraph under ‘Population’ subsection of 
methods cites two types of chart but uses the same reference for both. Please check and be 
consistent with the terms. 
 
3. 
There is quite a bit of repetition between the ‘Population’ and ‘Data extraction’ subsections 
of Methods. Please review and consider cutting. 
 
4. 
In ‘outcomes and variables’ you cite the key risk factors for SGA on which you collected data. 
You refer to the RCOG SGA guidance as rationalisation for this. However, RCOG guidance 
only defines ‘severe PIH’ (not all PIH) as a risk factor and doesn’t cite reduced fetal 
5. 
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movements as a risk factor in its screening algorithm. Please consider rephrasing this and 
justify why these factors (all PIH/reduced FM) have been included. 
 
In describing your choice of risk factors for SGA you also comment that choice was based on 
‘high level of completeness’. I wonder whether you mean ‘high prevalence’ and whether this 
is the reason that you haven’t included other co-morbidities such as CKD/diabetes, which 
both are major risk factors for SGA, but are present less commonly. 
 
6. 




In the second paragraph of ‘Data Analysis’ you have referenced paper 8, but I think this may 
be an error. 
 
8. 
Figure 1 doesn’t include the neonatal deaths – this confused me at first because there are 
only 9 stillbirths reported but the abstract reported that you had 12 perinatal deaths. It 
might be nice to add a box for neonatal deaths that were SGA/not. 
 
9. 
It would be nice to know how you determined that data on reduced fetal 
movements/PIH/PET or hypertension was missing, rather than just not a problem. In my 
experience, absence of a diagnosis is not the same as missing information – but perhaps 
SMR specifically codes absent diagnoses? 
 
10. 
In the paragraph just above the subsection on ‘Participating Units’ you list 2 of the 
denominators as ‘singleton births’ but the other as ‘Scottish births’. Presumably the latter 
includes multiple births and is not the same thing. Please check. 
 
11. 
In Table 3 – I think there is a typo for the p value of perinatal mortality. 
 
12. 
I am a bit uncertain about the adjustments made for the perinatal mortality model. You 
have concluded that there is no difference in perinatal mortality between detected and 
undetected SGA after adjusting for birthweight and gestational age (although there was 
without adjusting), which are outcomes as a result of SGA detection as well as potentially 
predictors in the case of perinatal mortality from severe SGA. The difference in this small 
number of deaths is likely be due to detection of severe SGA vs non-detection of borderline 
SGA. The relationship is quite complex and I can’t quite work out whether the approach is 
right – have you taken statistical advice on this? 
 
13. 
I am a little concerned regarding the case details shared in the penultimate paragraph. I 
think that women could be identified here – they are the only women with these specific 
characteristics in the whole of Scotland. Is this an information governance issue or do you 
have individual consent for case reporting?
14. 
To summarise, I think that most of this can be resolved quickly – but I would recommend more 
explanation and justification for decisions made in the paper.
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